These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 28673981)

  • 1. Synergistic effects of treating the spinal cord and brain in CLN1 disease.
    Shyng C; Nelvagal HR; Dearborn JT; Tyynelä J; Schmidt RE; Sands MS; Cooper JD
    Proc Natl Acad Sci U S A; 2017 Jul; 114(29):E5920-E5929. PubMed ID: 28673981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intrathecal enzyme replacement therapy improves motor function and survival in a preclinical mouse model of infantile neuronal ceroid lipofuscinosis.
    Lu JY; Nelvagal HR; Wang L; Birnbaum SG; Cooper JD; Hofmann SL
    Mol Genet Metab; 2015; 116(1-2):98-105. PubMed ID: 25982063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adeno-associated virus 2-mediated gene therapy decreases autofluorescent storage material and increases brain mass in a murine model of infantile neuronal ceroid lipofuscinosis.
    Griffey M; Bible E; Vogler C; Levy B; Gupta P; Cooper J; Sands MS
    Neurobiol Dis; 2004 Jul; 16(2):360-9. PubMed ID: 15193292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic effects of central nervous system-directed gene therapy and bone marrow transplantation in the murine model of infantile neuronal ceroid lipofuscinosis.
    Macauley SL; Roberts MS; Wong AM; McSloy F; Reddy AS; Cooper JD; Sands MS
    Ann Neurol; 2012 Jun; 71(6):797-804. PubMed ID: 22368049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CNS-directed AAV2-mediated gene therapy ameliorates functional deficits in a murine model of infantile neuronal ceroid lipofuscinosis.
    Griffey MA; Wozniak D; Wong M; Bible E; Johnson K; Rothman SM; Wentz AE; Cooper JD; Sands MS
    Mol Ther; 2006 Mar; 13(3):538-47. PubMed ID: 16364693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cln1-mutations suppress Rab7-RILP interaction and impair autophagy contributing to neuropathology in a mouse model of infantile neuronal ceroid lipofuscinosis.
    Sarkar C; Sadhukhan T; Bagh MB; Appu AP; Chandra G; Mondal A; Saha A; Mukherjee AB
    J Inherit Metab Dis; 2020 Sep; 43(5):1082-1101. PubMed ID: 32279353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cln3-mutations underlying juvenile neuronal ceroid lipofuscinosis cause significantly reduced levels of Palmitoyl-protein thioesterases-1 (Ppt1)-protein and Ppt1-enzyme activity in the lysosome.
    Appu AP; Bagh MB; Sadhukhan T; Mondal A; Casey S; Mukherjee AB
    J Inherit Metab Dis; 2019 Sep; 42(5):944-954. PubMed ID: 31025705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histochemical localization of palmitoyl protein thioesterase-1 activity.
    Dearborn JT; Ramachandran S; Shyng C; Lu JY; Thornton J; Hofmann SL; Sands MS
    Mol Genet Metab; 2016 Feb; 117(2):210-6. PubMed ID: 26597320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cln1 gene disruption in mice reveals a common pathogenic link between two of the most lethal childhood neurodegenerative lysosomal storage disorders.
    Chandra G; Bagh MB; Peng S; Saha A; Sarkar C; Moralle M; Zhang Z; Mukherjee AB
    Hum Mol Genet; 2015 Oct; 24(19):5416-32. PubMed ID: 26160911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative proteomic profiling reveals mechanisms for early spinal cord vulnerability in CLN1 disease.
    Nelvagal HR; Hurtado ML; Eaton SL; Kline RA; Lamont DJ; Sands MS; Wishart TM; Cooper JD
    Sci Rep; 2020 Sep; 10(1):15157. PubMed ID: 32938982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination small molecule PPT1 mimetic and CNS-directed gene therapy as a treatment for infantile neuronal ceroid lipofuscinosis.
    Roberts MS; Macauley SL; Wong AM; Yilmas D; Hohm S; Cooper JD; Sands MS
    J Inherit Metab Dis; 2012 Sep; 35(5):847-57. PubMed ID: 22310926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ppt1-deficiency dysregulates lysosomal Ca
    Mondal A; Appu AP; Sadhukhan T; Bagh MB; Previde RM; Sadhukhan S; Stojilkovic S; Liu A; Mukherjee AB
    J Inherit Metab Dis; 2022 May; 45(3):635-656. PubMed ID: 35150145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The novel Cln1(R151X) mouse model of infantile neuronal ceroid lipofuscinosis (INCL) for testing nonsense suppression therapy.
    Miller JN; Kovács AD; Pearce DA
    Hum Mol Genet; 2015 Jan; 24(1):185-96. PubMed ID: 25205113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathogenesis and therapies for infantile neuronal ceroid lipofuscinosis (infantile CLN1 disease).
    Hawkins-Salsbury JA; Cooper JD; Sands MS
    Biochim Biophys Acta; 2013 Nov; 1832(11):1906-9. PubMed ID: 23747979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An anti-neuroinflammatory that targets dysregulated glia enhances the efficacy of CNS-directed gene therapy in murine infantile neuronal ceroid lipofuscinosis.
    Macauley SL; Wong AM; Shyng C; Augner DP; Dearborn JT; Pearse Y; Roberts MS; Fowler SC; Cooper JD; Watterson DM; Sands MS
    J Neurosci; 2014 Sep; 34(39):13077-82. PubMed ID: 25253854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AAV2-mediated ocular gene therapy for infantile neuronal ceroid lipofuscinosis.
    Griffey M; Macauley SL; Ogilvie JM; Sands MS
    Mol Ther; 2005 Sep; 12(3):413-21. PubMed ID: 15979943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human recombinant palmitoyl-protein thioesterase-1 (PPT1) for preclinical evaluation of enzyme replacement therapy for infantile neuronal ceroid lipofuscinosis.
    Lu JY; Hu J; Hofmann SL
    Mol Genet Metab; 2010 Apr; 99(4):374-8. PubMed ID: 20036592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuroprotection of host cells by human central nervous system stem cells in a mouse model of infantile neuronal ceroid lipofuscinosis.
    Tamaki SJ; Jacobs Y; Dohse M; Capela A; Cooper JD; Reitsma M; He D; Tushinski R; Belichenko PV; Salehi A; Mobley W; Gage FH; Huhn S; Tsukamoto AS; Weissman IL; Uchida N
    Cell Stem Cell; 2009 Sep; 5(3):310-9. PubMed ID: 19733542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive functional characterization of murine infantile Batten disease including Parkinson-like behavior and dopaminergic markers.
    Dearborn JT; Harmon SK; Fowler SC; O'Malley KL; Taylor GT; Sands MS; Wozniak DF
    Sci Rep; 2015 Aug; 5():12752. PubMed ID: 26238334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deficiency of the INCL protein Ppt1 results in changes in ectopic F1-ATP synthase and altered cholesterol metabolism.
    Lyly A; Marjavaara SK; Kyttälä A; Uusi-Rauva K; Luiro K; Kopra O; Martinez LO; Tanhuanpää K; Kalkkinen N; Suomalainen A; Jauhiainen M; Jalanko A
    Hum Mol Genet; 2008 May; 17(10):1406-17. PubMed ID: 18245779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.